Adamis Pharmaceuticals Co... (ADMP)
NASDAQ: ADMP
· Real-Time Price · USD
0.78
0.01 (1.50%)
At close: Sep 07, 2023, 9:59 PM
Adamis Pharmaceuticals Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 6.66B | 640.25K | 3.1M | 1.08M | 2.42M | 8.88M | 17.77M | 23.22M | 28.73M | 40.62M | 57.92M |
Short-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 9.67M | 9.67K | 52.17K | 52.17K | 52.17K | 52.17K | 52.17K | 109.14K | 97.55K | 54.66K | 54.66K |
Receivables | n/a | 18.97K | 21.17K | 1.09M | 1.55M | 956.07K | 4.6M | 5.9M | 7.1M | 1.31M | 1.19M |
Inventory | 662.96M | 664.36K | 664.36K | 1.24M | 1.09M | 440.2K | 32K | 418.61K | 5.18M | 2.17M | 2.56M |
Other Current Assets | 545.18M | 658.12K | 750.27K | 893.93K | 803.41K | 795.84K | 1.08M | 215.3K | 891.46K | 2M | 975.57K |
Total Current Assets | 7.87B | 3.45M | 7.55M | 9.27M | 10.09M | 15.32M | 27.79M | 35.2M | 41.9M | 46.13M | 62.65M |
Property-Plant & Equipment | 1.08B | 1.29M | 1.48M | 1.61M | 2M | 2.32M | 2.71M | 2.99M | 3.08M | 10.84M | 11.04M |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 6.68M | 6.92M |
Total Long-Term Assets | 1.09B | 1.3M | 1.53M | 1.66M | 2.05M | 2.37M | 2.76M | 3.09M | 3.18M | 17.58M | 18.01M |
Total Assets | 8.96B | 4.75M | 9.08M | 10.93M | 12.14M | 17.69M | 30.55M | 38.3M | 45.08M | 63.71M | 80.66M |
Account Payables | 9.97B | 11.37M | 9.78M | 7.94M | 5.3M | 4.52M | 4.89M | 3.75M | 2.45M | 3.01M | 4.04M |
Deferred Revenue | 172.78M | 174.9K | 27.78K | 27.78K | 27.78K | 100K | 100K | 100K | 100K | 104.1K | 120.69K |
Short-Term Debt | 63.21M | 157.25K | 250.36K | 342.56K | 368.81K | 362.43K | 2.21M | 349.87K | 343.74K | 5.91M | 5.47M |
Other Current Liabilities | 3.25B | 3.31M | 2.89M | 3.09M | 3.18M | 4.75M | 6.39M | 7.02M | 6.3M | 4.43M | 11.69M |
Total Current Liabilities | 13.46B | 15.01M | 12.95M | 11.4M | 8.87M | 9.72M | 13.58M | 11.22M | 9.2M | 13.45M | 21.32M |
Long-Term Debt | n/a | n/a | n/a | n/a | 63.21K | 157.25K | 250.36K | 342.56K | 432.02K | 2.42M | 3.01M |
Other Long-Term Liabilities | 302.17M | 1.4M | 5.64M | 164.79K | 169.34K | 70.73K | 90.27K | 99.66K | 202.3K | 244.82K | 201.25K |
Total Long-Term Liabilities | 459.58M | 1.57M | 5.81M | 343.04K | 417.74K | 927.97K | 1.07M | 1.19M | 1.41M | 3.58M | 4.15M |
Total Liabilities | 13.92B | 16.57M | 18.76M | 11.74M | 9.29M | 10.65M | 14.65M | 12.42M | 10.61M | 17.03M | 25.46M |
Total Debt | 63.21M | 157.25K | 250.36K | 342.56K | 432.02K | 519.68K | 2.46M | 692.43K | 775.75K | 8.33M | 8.48M |
Common Stock | 1.01M | 15.83K | 15.05K | 15.05K | 15.05K | 15.05K | 15.03K | 15.01K | 14.94K | 14.94K | 14.94K |
Retained Earnings | -323.47B | -322.08M | -313.51M | -304.56M | -301.24M | -296.84M | -288.44M | -278.09M | -269.31M | -256.95M | -247.64M |
Comprehensive Income | -330M | -345.83K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shareholders Equity | -4.96B | -11.83M | -9.68M | -808.07K | 2.85M | 7.04M | 15.9M | 25.88M | 34.47M | 46.68M | 55.19M |
Total Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |